93 results about "Foam cell" patented technology

New methods of ultrasound imaging are presented that provide images with reduced reverberation noise and images of nonlinear scattering and propagation parameters of the object, and estimation of corrections for wave front aberrations produced by spatial variations in the ultrasound propagation velocity. The methods are based on processing of the received signal from transmitted dual frequency band ultrasound pulse complexes with overlapping high and low frequency pulses. The high frequency pulse is used for the image reconstruction and the low frequency pulse is used to manipulate the nonlinear scattering and / or propagation properties of the high frequency pulse. A 1st method uses the scattered signal from a single dual band pulse complex for filtering in the fast time (depth time) to provide a signal with suppression of reverberation noise and with 1st harmonic sensitivity and increased spatial resolution. In other methods two or more dual band pulse complexes are transmitted where the frequency and / or the phase and / or the amplitude of the low frequency pulse vary for each transmitted pulse complex. Through filtering in the pulse number coordinate and corrections of nonlinear propagation delays and optionally also amplitudes, a linear back scattering signal with suppressed pulse reverberation noise, a nonlinear back scattering signal, and quantitative nonlinear scattering and forward propagation parameters are extracted. The reverberation suppressed signals are further useful for estimation of corrections of wave front aberrations, and especially useful with broad transmit beams for multiple parallel receive beams. Approximate estimates of aberration corrections are given. The nonlinear signal is useful for imaging of differences in tissue properties, such as micro-calcifications, in-growth of fibrous tissue or foam cells, or micro gas bubbles as found with decompression or injected as ultrasound contrast agent.

The present invention provides a compound of the formula (I):wherein R1, R2, R3 and R4 are each independently hydrogen, optionally substituted alkyl, hydroxy, optionally substituted alkoxy or the like, R5 is optionally substituted alkyl, optionally substituted aryl, optionally substituted heterocyclic or the like, R6 is hydrogen, optionally substituted alkyl or the like, R7 is hydrogen, optionally substituted alkyl, optionally substituted alkoxy, optionally substituted aryl, optionally substituted heterocyclic or the like, A is S or O and a broken line represents presence or absence of a bond,pharmaceutically acceptable salt or hydrate thereof and a pharmaceutical composition or a pharmaceutical composition for use as an endothelin receptor antagonist, a peripheral circulation insufficiency-improving agent or a macrophage foam cell formation inhibitor comprising the compound.

Cell nucleation compositions and pellets, methods for making same, methods and compositions for making polymer foam, and polymer foams made by the methods are disclosed.

The present invention relates to a hydrophilic foam material, which is of particular use in wound treatment, and to a method for producing said hydrophilic foam material. The hydrophilic foam material has nucleating particles, wherein at least 85% of all foam cells in said foam material have an average cell size of 0.01 mm2 or less.

The present invention relates to the use of a composition comprising a combination of diacylglycerol(s) (DAG), mainly 1,3-diacylglycerol(s), and phytosterol and / or phytostanol ester(s) (PSE) dissolved or dispersed in edible oil and / or edible fat, in the manufacture of nutritional supplements and orally administrable pharmaceutical preparations which are capable of reducing blood levels of both cholesterol and triglycerides and / or for lowering serum, serum LDL and macrophage oxidation levels, inhibiting the formation of foam cells and / or preventing the deleterious effects generated by lipid-induced oxidative stress. In addition, the composition of the invention, as well as the pharmaceutical preparations thereof, is suitable for the treatment and prevention of conditions related to atherosclerosis, such as cardiovascular disease (CVD), coronary heart disease (CHD) and diabetes mellitus.

A wound treatment-dressing is shown which includes a dressing body formed from a medically inert, moisture permeable, urethane open-cell foam which is hydrophilic in nature. The foam body has a foam matrix of interconnected foam cells with cell walls which have incorporated therein a combination of inorganic antimicrobials as active agents, the active agents being incorporated into the foam matrix both topically on a foam cell surface and integrally within the foam cell wall. The antimicrobials are manufactured in a selected particle size range which improves predictability and performance of the wound dressing.